Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
South Korea will invest 520 billion won in biotechnology next year to boost its development of treatment and vaccines for COVID-19.
The Ministry of Science and ICT said the figure represents a 24.9 percent hike from 2020.
Of that amount, 31.7 billion won will go to COVID-19 treatment and vaccine development and 10.2 billion won for technology to respond to new infectious diseases.
Some of it will also go to research into new core biotech industries, such as 71 billion won to develop a new medicine, 61.8 billion won in medical devices, and 31.1 billion won in regenerative medicine to strengthen research in stem cell technology and others.
The medical devices to be developed targets the elderly and the disabled.
The ministry said it also plans to invest 51.3 billion won to acquire next-generation biotech, such as single-cell analysis.
Last month, 36 South Korean biotech and pharmaceutical companies announced that they invest a combined 10 trillion won by 2023 to hone their competitiveness and technological capabilities.
The firms include Samsung Biologics Co. and Celltrion Inc., will
The government intends to spend a total of 2.2 trillion won on developing new medicine until 2030.
